Lactobacillus Paracasei K56 for Cytokine-Modulated Colitis Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for enteritis, including traditional medical and Chinese herbal remedies, lack a clear mechanism of action for alleviating intestinal inflammation, and probiotics, while effective, require further elucidation on their immune regulation and mucosal barrier strengthening effects.
Innovation Solution
The use of Lactobacillus paracasei subsp. paracasei K56, deposited as DSM 27447 and CGMCC 15139, is effective in reducing inflammatory factors IL-6 and TNF-α, promoting anti-inflammatory factor IL-10, and minimizing tissue damage in colitis through specific dosages in compositions such as food, feed, or pharmaceutical formulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional medical treatment or Chinese herbal treatment is used for enteritis, then treatment effects are achieved, but the mechanism of action for alleviating intestinal inflammation is not clear
Solution Approach 1:
The patent employs feedback by measuring cytokine levels (IL-6, TNF-α, IL-10) before and after treatment to evaluate the mechanism of action. The probiotic treatment effect is assessed through feedback loops that monitor inflammatory marker changes, providing mechanistic insight while confirming treatment efficacy.
2Object-affected harmful factors
If probiotics are used to regulate intestinal flora balance, then intestinal inflammation is reduced, but the specific immune regulation and mucosal barrier strengthening effects require further elucidation
Solution Approach 1:
The patent uses feedback mechanisms to measure and evaluate immune regulation effects by monitoring cytokine levels (IL-6, TNF-α, IL-10) in serum and intestinal tissue. This feedback approach elucidates the specific immune regulation mechanisms while confirming the reduction of intestinal inflammation.
Solution Approach 2:
The patent introduces cytokine measurement as an intermediary to bridge the gap between probiotic administration and immune regulation effects. By measuring intermediate markers (inflammatory cytokines), the patent elucidates the mechanism through which probiotics strengthen mucosal barriers and regulate immune responses.
3Reliability
If a specific probiotic strain Lactobacillus paracasei subsp. paracasei K56 is used, then inflammatory factors IL-6 and TNF-α are decreased and anti-inflammatory factor IL-10 is promoted, but the need for standardized dosage and formulation remains
Solution Approach 1:
The patent applies parameter changes by establishing specific dosage ranges (1×10^8 to 1×10^13 CFU/day) and formulation parameters for Lactobacillus paracasei subsp. paracasei K56. This standardization of critical parameters ensures reliable anti-inflammatory effects while simplifying formulation complexity through defined specifications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Lactobacillus paracasei subsp. paracasei K56 significantly reduces intestinal inflammation by decreasing IL-6 and TNF-α levels, increasing IL-10 production, and mitigating tissue damage in colitis, demonstrating broad applicability in food, drug, and feed compositions.
Implementation Method 1
probiotics are able to antagonize pathogenic bacteria, safe, controllable, and effective, and have few side effects, making them an ideal treatment for enteritis. The mechanism of probiotic treatment of enteritis is not well elucidated yet, but is generally attributed to the fact that probiotics can inhibit colonization of pathogenic bacteria through competition for nutrients and co-receptors, or directly inhibit pathogenic bacteria by production of bacteriocins, or isolate pathogenic bacteria and their toxins by production of antitoxin proteases.
Implementation Method 2
the strain Lactobacillus paracasei subsp. paracasei K56 alone is efficacious at alleviating intestinal inflammation, decreasing the level of inflammatory factors IL-6 and/or TNF-α, promoting anti-inflammatory factor IL-10, and reducing tissue damage in colitis.
Data Source
AI summary
The present invention provides novel use of Lactobacillus paracasei subsp. paracasei K56 in alleviation of intestinal inflammation. Lactobacillus paracasei subsp. paracasei K56 of the present invention has the deposit number CGMCC 15139 or DSM 27447. It was discovered in the present invention that the strain alone was highly efficacious at alleviating intestinal inflammation, reducing inflammatory factors IL-6 and/or TNF-α, promoting the anti-inflammatory factor IL-10, and reducing the tissue damage of colitis.